Incidence of exposure to drugs for which pre-emptive pharmacogenomic testing is available

Objective: Derive data that large healthcare organizations can combine with data on risks of adverse events and cost data to conduct cost-effectiveness / cost-benefit analyses for pre-emptive pharmacogenomics testing

Rationale: Very few studies have been conducted that report on the potential return on investment for pre-emptive pharmacogenomics testing. The studies that have been published suggest that pre-emptive pharmacogenomics testing may produce a return on investment but much depends on if a sufficient number of drugs with pharmacogenes are covered by a single test. Since the current data are limited to relatively localized settings and might not be of generalizable use to other health organizations, it's of interest to implement a new study using the OHDSI research network.

Project Lead(s): Richard D. Boyce, Matthias Samwald

Coordinating Institution(s): University of Pittsburgh, Medical University of Vienna, Columbia University, Regenstrief Institute, Janssen R&D, AstraZeneca

Additional Participants (currently seeking other collaborators): Patrick Ryan, Jon Duke, George Hripcsak, Abraham G. Hartzema, Christian Reich, Dan Malone

Full Protocol: Google doc for the protocol

Initial Proposal Date: 2/16/2015

Launch Date: This was a test research network study and has met its objectives as of 12/1/2016.

Study Closure Date: <fill out once finalized>

Results Submission: <method of sumission, eg. Email or SFTP>